Anal squamous cell carcinoma

1. Introduction and Epidemiology

Anal squamous cell carcinoma (ASCC) is a malignant neoplasm arising from the squamous epithelium of the anal canal or perianal skin. It represents the most common histological subtype of anal cancer, accounting for approximately 80–85% of all primary anal malignancies. While relatively rare compared to colorectal cancer—comprising roughly 2–4% of all gastrointestinal malignancies and 0.5% of all new cancer diagnoses globally—its incidence has been rising steadily over the past three decades, particularly in high-income countries.

Key Epidemiological Features

• Incidence: Estimated 1.5 to 2.5 per 100,000 person-years in Western nations.
• Gender Disparity: Historically higher in women (female-to-male ratio ~1.5:1), though rates in men who have sex with men (MSM) are significantly elevated, often exceeding cervical cancer rates in this subgroup prior to widespread screening.
• Age Distribution: Peak incidence occurs in the 6th and 7th decades of life (median age at diagnosis: 62–65 years). It is rare before age 35.
• Geographic Variation: Higher rates in North America, Europe, and Australia; lower rates in Asia and Africa.

Clinical Pearl:** The rising incidence is largely attributed to changing sexual practices, increased prevalence of Human Papillomavirus (HPV) infection, and the aging HIV-positive population (due to effective antiretroviral therapy prolonging life but not eliminating oncogenic risk).

2. Aetiology and Risk Factors

The pathogenesis of ASCC is strongly linked to persistent infection with high-risk oncogenic Human Papillomavirus (HPV), specifically HPV-16 and HPV-18, which are detected in 85–95% of tumour specimens. The viral oncoproteins E6 and E7 inactivate tumour suppressor proteins p53 and pRb, respectively, driving genomic instability and malignant transformation.

Major Risk Factors

3. Anatomy and Histopathological Classification

Understanding the anatomical boundaries is critical for staging and treatment planning.

Anatomical Definitions (AJCC / UICC TNM 8th Edition)

• Anal Canal: The segment extending from the anorectal ring (palpable puborectalis sling) distally to the anal verge (muco-cutaneous junction). Length: 2–4 cm.
• Perianal Region (Anal Margin): Skin within a 5 cm radius of the anal verge. Lesions here are staged as skin cancers (if keratinizing) or anal canal cancers (if non-keratinizing/transitional), but treatment paradigms often align.
• Squamous Columnar Junction (SCJ) / Transformation Zone: Analogous to the cervix, this is the primary site of HPV-related carcinogenesis.

WHO Histological Classification (2022 Update)

ASCC is no longer a single entity but a spectrum. The term “Cloacogenic carcinoma” is obsolete.

Biomarker Note: p16^INK4a Immunohistochemistry (IHC)** is the standard surrogate marker for transcriptionally active HPV infection. Diffuse strong nuclear and cytoplasmic staining supports HPV-driven aetiology and carries prognostic weight.

4. Precancerous Lesions: Anal Intraepithelial Neoplasia (AIN)

ASCC arises predominantly through a stepwise progression from precursor lesions termed Anal Intraepithelial Neoplasia (AIN), now increasingly classified using a two-tiered system (LSIL/HSIL) analogous to cervical pathology.

The Bethesda System / LAST Project Terminology

Screening Target Populations: HIV+ MSM (start age 35), HIV+ Women/MSM non-MSM (start age 45), Transplant recipients, History of cervical/vulvar HSIL/cancer. Screening modality: Anal Cytology + High-Resolution Anoscopy (HRA).

5. Clinical Presentation: Symptoms

The clinical presentation of ASCC is often insidious, leading to diagnostic delays averaging 3–6 months. Symptoms frequently mimic benign anorectal conditions (haemorrhoids, fissures, fistulas), resulting in misdiagnosis or delayed referral.

Local Symptoms (Most Common)

• Rectal / Anal Bleeding: The cardinal symptom (reported in 45–65% of patients). Typically bright red, small volume, coating the stool or on toilet paper. Often attributed to “piles.”
• Perianal Pain / Discomfort: Present in 30–50%. May be constant, dull, aching, or sharp during defecation (tenesmus). Progressive, unremitting pain suggests deep sphincter invasion or nerve involvement.
• Palpable Mass / Lump: Felt by patient or clinician (20–40%). May be ulcerated, firm, fixed, or friable.
• Pruritus Ani (Anal Itching): Chronic, refractory to standard topical therapy. Present in 15–25%.
• Altered Bowel Habits / Tenesmus: Narrowing of stool calibre (pencil-thin stools), sensation of incomplete evacuation, mucus discharge.
• Faecal Incontinence / Soiling: Late sign indicating internal anal sphincter (IAS) invasion or significant tumour bulk distorting the continence mechanism.

Systemic / Advanced Symptoms

• Inguinal Lymphadenopathy: Palpable, firm, often fixed nodes in the groin (superficial inguinal nodes). Indicates regional nodal metastasis (N1/N2). Occurs in 15–25% at presentation.
• Pelvic Pain / Sciatica: Suggests invasion of the pelvic sidewall, obturator internus, or sacral plexus (T4 disease).
• Urinary Symptoms: Frequency, urgency, retention, or haematuria suggesting bladder/urethral invasion (T4).
• Constitutional Symptoms: Weight loss, fatigue, anorexia (advanced/metastatic disease).

Symptom Frequency Summary Table

Red Flag: Any patient >40 years with “haemorrhoidal” symptoms failing to respond to 4–6 weeks of conservative management must** undergo rigid proctoscopy/examination under anaesthesia (EUA) to exclude malignancy.

6. How Does It Look: Physical Appearance and Endoscopic Findings

Visual recognition is paramount. The appearance varies significantly based on tumour subtype, location (canal vs. margin), and stage.

Gross Morphological Types (Macroscopic Classification)

Location-Specific Appearance

A. Anal Canal (Proximal to Anal Verge)

• Visualization: Requires Rigid Proctoscopy, Anoscopy, or High-Resolution Anoscopy (HRA).
• Appearance: Lesions often circumferentially involve the transformation zone (dentate line to anorectal ring).
• HRA Findings (Acetic Acid 3–5% + Lugol’s Iodine):
• Acetowhite Epithelium: Dense, opaque white lesions appearing within 60–90 seconds of acetic acid application = HSIL / Early Cancer.
• Mosaic Pattern: Vascular network resembling tiles.
• Punctation: Fine red dots (capillary loops) on white background.
• Atypical Vessels: Corkscrew, branching, dilated, irregular calibre vessels = High suspicion for Invasion.
• Lugol’s Non-Uptake (Schiller’s Test): HSIL/Cancer remains pale/yellow (glycogen negative); normal squamous epithelium stains brown/black.

B. Perianal Skin / Anal Margin (Distal to Anal Verge)

• Visualization: Direct inspection, good lighting, magnification (dermoscopy helpful).
• Appearance:
• Leukoplakia: White, hyperkeratotic plaque (cannot be scraped off). High risk for keratinizing SCC.
• Erythroplasia of Queyrat: Velvety, red, well-demarcated plaque (Bowen’s disease / SCC in situ).
• Ulcerated Nodule: Firm, indurated base, rolled edges, often mistaken for chronic fissure or granuloma.
• Verrucous Mass: Large, exophytic, “cauliflower” growth (Verrucous carcinoma).
• Dermoscopy Features (Non-invasive aid): Glomerular vessels (red dots), hairpin vessels with white halo, structureless white areas (hyperkeratosis), hemorrhagic spots.

Differential Diagnosis: Visual Mimics

7. Diagnostic Workup

Tissue Diagnosis (Mandatory)

• Incisional Biopsy: Gold standard. Performed in clinic (local anaesthetic) or EUA. Multiple biopsies if lesion large/heterogeneous.
• Core Needle Biopsy (Inguinal Nodes): If palpable nodes present (FNAC insufficient for architecture/HPV status).
• Pathology Report Must Include: Histological subtype, Grade (well/moderate/poor), Depth of invasion (mm), Lymphovascular invasion (LVI), Perineural invasion (PNI), p16 IHC status, Margins (if excision biopsy).

Local Staging (T-Stage)

• MRI Pelvis (High-Resolution, T2-weighted): Gold standard for local staging. Assesses:
• Tumour size (max diameter).
• Sphincter involvement: IAS (low signal on T2) vs EAS (intermediate signal).
• Intersphincteric plane breach.
• Levator ani / Pelvic sidewall invasion.
• Mesorectal fascia involvement.
• Endoanal Ultrasound (EAUS): Alternative if MRI contraindicated. Excellent for sphincter detail, operator-dependent, poor for nodal/extrapelvic assessment.
• Examination Under Anaesthesia (EUA): Essential for accurate clinical T-staging, sphincter tone assessment, and biopsy if office exam inadequate.

Regional / Distant Staging (N / M Stage)

• CT Chest/Abdomen/Pelvis (CAP): Standard for nodal (pelvic/inguinal) and distant (liver/lung) mets.
• PET-CT (FDG): Highly Recommended (NCCN/ESMO). Superior sensitivity for:
• Occult inguinal/pelvic nodes (upstages 15–20%).
• Distant metastases.
• Radiation planning (GTV delineation).
• Baseline for response assessment.
• Inguinal Node Ultrasound + FNAC/Core: If PET-CT equivocal or not available.

Baseline Workup Pre-Treatment

• FBC, U&E, LFT, Coagulation, HIV Serology (if status unknown), CD4 count (if HIV+).
• Fertility counselling / Sperm banking (males) / Ovarian transposition discussion (females <45).
• Stoma counselling (colostomy potential for salvage/APR).
• Dental review (if mandibular radiation field possible – rare for anal).

8. Staging System (AJCC 8th Edition / UICC 8th Edition)

Staging dictates prognosis and treatment intensity.

Primary Tumour (T)

Regional Lymph Nodes (N)

Distant Metastasis (M)

• M0: No distant metastasis.
• M1: Distant metastasis (Liver, Lung, Bone, Non-regional nodes, Peritoneum).

Stage Grouping

9. Management: The Standard of Care

Definitive Chemoradiation (CRT) – The “Nigro Protocol” Legacy

Primary treatment for Stage I–III (Non-metastatic). Surgery (APR) is reserved for salvage. Organ preservation is the primary goal.

Radiation Therapy (RT)

• Technique: IMRT (Intensity-Modulated Radiation Therapy) or VMAT (Volumetric Modulated Arc Therapy) mandatory to spare bowel, bladder, genitalia, femoral heads, bone marrow.
• Dose:
• Primary Tumour (GTV): 50.4 – 54 Gy (1.8 Gy/fx).
• Elective Nodal Volumes (Pelvic + Inguinal): 45 – 50.4 Gy.
• Boost (if residual disease at 6–12 wks): Up to 54–60 Gy (controversial, often omitted if complete response).
• Field Design: “Dog-leg” fields historically; now conformal wrapping around target volumes.

Chemotherapy (Concurrent)

• Standard Regimen (US/UK/EU):
• 5-Fluorouracil (5-FU) 1000 mg/m²/day Continuous Infusion (CI) Days 1–4 & 29–32 (or oral Capecitabine 825 mg/m² BID Days 1–5 & 29–33).
• Mitomycin C (MMC) 10–12 mg/m² IV Day 1 (Cycle 1 only).
• Alternative (Reduced Toxicity / Renal Impairment): 5-FU/Cisplatin (less used now due to nephro/neurotoxicity).
• HIV+ Patients: Same regimen; continue ART; monitor counts closely (G-CSF support often needed).

Treatment Timeline & Assessment

1. Baseline: MRI/PET, EUA, Biopsy.
2. CRT Delivery: 5–5.5 weeks.
3. First Response Assessment: 12–16 weeks post-CRT completion (Critical wait: early biopsy causes false positives due to inflammation/fibrosis).

• Clinical Complete Response (cCR): No visible tumour, normal exam, MRI/PET negative.
• Surveillance: DRE/Anoscopy q3-6mo x 2yrs, then q6-12mo x 3yrs. MRI/PET at 6-12mo.

1. Persistent/Residual Disease at 12-16 wks: Biopsy proven residual -> Salvage Surgery (APR).

Surgical Roles

Management of Metastatic / Recurrent Disease (Stage IV / Salvage Failure)

• Systemic Therapy (Palliative):
• 1st Line: Carboplatin + Paclitaxel (Preferred: better toxicity profile) OR Cisplatin + 5-FU.
• Immunotherapy: Pembrolizumab / Nivolumab (Anti-PD-1) approved for PD-L1+ (CPS ≥ 1 or ≥ 10) or MSI-H/dMMR tumours after platinum failure (KEYNOTE-158, CheckMate 358). Response rates ~15-20%, but durable.
• 2nd Line+: Clinical trials, Docetaxel, Gemcitabine.
• Oligometastatic Disease: Aggressive local therapy (SBRT/Surgery) to limited mets + systemic therapy – emerging paradigm.
• Palliative RT: For bleeding, pain, obstruction, nerve compression.

10. Toxicity Management and Survivorship

CRT carries significant acute and long-term morbidity. Proactive management is essential for quality of life (QoL).

Acute Toxicities (During / 0–3 Months Post-CRT)

Late / Long-Term Toxicities (> 3 Months)

• Anal Stricture / Stenosis: Fibrosis narrowing canal. Dilatation (graded bougies/balloons) mainstay. Prevention: Early anal dilatators post-CRT?
• Chronic Faecal Incontinence / Urgency: Sphincter fibrosis + neuropathy + rectal reservoir loss. Sacral Neuromodulation (SNM), Biofeedback, Bulking agents, Colostomy (last resort).
• Sexual Dysfunction:
• Women: Vaginal stenosis, dryness, dyspareunia, ovarian failure (prem menopause). Vaginal Dilators (start 2-4 wks post-RT), Topical Estrogen, Lubricants.
• Men: Erectile dysfunction (vascular/neural), Ejaculatory dysfunction. PDE5 inhibitors, Vacuum devices.
• Bone Health: Pelvic insufficiency fractures (sacrum/pubic rami). DEXA scan, Calcium/Vit D, Bisphosphonates/Denosumab if osteoporotic.
• Secondary Malignancies: Risk increased in radiation field (sarcoma, bladder, rectal) – latency 10+ years.
• Lymphoedema: Lower limb / genital (if inguinal RT + ILND). Compression garments, Manual Lymphatic Drainage (MLD).

Surveillance Schedule (Post-CRT cCR)

Survivorship Focus:** Multidisciplinary clinic (Oncology, Colorectal, Nursing, Physiotherapy, Psychosexual Counselling, Stoma Therapy) improves functional outcomes and QoL.

11. Special Populations

HIV-Positive Patients

• Standard of Care: Same CRT regimen as HIV-negative if CD4 > 200 cells/µL and on effective ART.
• CD4 < 200: Consider dose-reduced chemo (omit MMC or reduce 5-FU) or RT alone (inferior outcomes). G-CSF primary prophylaxis strongly recommended.
• Outcomes: Similar local control and OS to HIV-negative if CD4 preserved. Higher acute haematologic toxicity.
• Drug Interactions: ART (Protease Inhibitors, NNRTIs) ↔ Chemo/Metabolism. Pharmacist review mandatory.

Solid Organ Transplant Recipients

• Higher risk of rejection during CRT (immune stimulation + lymphodepletion).
• Close coordination with Transplant Team. Tacrolimus/Ciclosporin levels fluctuate with mucositis/diarrhoea.
• Higher risk of aggressive disease and secondary skin cancers.

Pregnancy

• 1st Trimester: Termination usually advised if curative CRT needed (Teratogenicity of Chemo/RT).
• 2nd/3rd Trimester: Delay CRT if feasible (fetal maturity). RT shielding difficult. Neoadjuvant Chemo (Cisplatin/5-FU) possible after 1st trimester. Delivery -> CRT. Multidisciplinary (Maternal-Fetal Med, Neonatology) essential.

12. Prognosis and Predictive Factors

Favourable Prognostic Factors

• HPV/p16 Positive (Basaloid histology).
• T1/T2 Stage (Tumour ≤ 5 cm).
• N0 Stage (No nodal involvement).
• Female Sex (Independent of stage).
• Complete Clinical Response (cCR) to CRT at 12–16 weeks.
• No LVI / PNI on biopsy.
• HIV-negative or HIV+ with CD4 > 500 / Undetectable VL.

Unfavourable Prognostic Factors

• HPV/p16 Negative (Keratinizing histology).
• T3/T4 Stage (>5 cm or Organ invasion).
• N+ Stage (Inguinal > Pelvic nodes worse).
• Male Sex (Partially explained by HPV status/MSM epidemiology).
• Persistent Disease post-CRT (requires APR).
• Immunosuppression (Transplant, Low CD4).
• High Tumour Mutational Burden (TMB) / Specific mutations (TP53, PIK3CA, EGFR – research context).

Survival Statistics (Contemporary Series, CRT Era)

• 5-Year Overall Survival (OS): Stage I: ~85–90%; Stage II: ~75–80%; Stage III: ~55–65%; Stage IV: ~20–30%.
• Colostomy-Free Survival (CFS): Stage I/II: ~75–85%; Stage III: ~55–65%.
• Cause of Death: Locoregional recurrence (salvage failure) > Distant Metastasis > Intercurrent/Non-cancer (esp. HIV+, Elderly).

13. Prevention and Screening

HPV Vaccination

• Primary Prevention: 9-valent HPV Vaccine (Gardasil 9) covers HPV 6, 11, 16, 18, 31, 33, 45, 52, 58.
• Indications: All genders, Ages 9–26 (Routine), 27–45 (Shared decision making).
• Impact: Proven to reduce anal HPV infection, AIN 2/3, and ASCC in males and females. Most effective before sexual debut / HPV exposure.
• HIV+ Individuals: 3-dose schedule regardless of age. Immunogenicity lower but significant benefit demonstrated.

Screening High-Risk Groups (Secondary Prevention)

• Target: HIV+ MSM (Age 35+), HIV+ Women/MSM non-MSM (Age 45+), Transplant Recipients, Prior Lower Genital Tract HSIL/Cancer.
• Modality: Anal Cytology (Pap) + High-Resolution Anoscopy (HRA).
• Algorithm:
• Normal Cytology -> Repeat in 1–3 years (HIV+) / 3–5 years (Other).
• ASC-US / LSIL -> HRA. Treat HSIL on HRA. Observe LSIL.
• HSIL on Cytology -> HRA + Treat HSIL.
• ASC-H / Atypical Glandular Cells -> HRA + Biopsy mandatory.
• Evidence: The ANCHOR Study (NEJM 2022) demonstrated that treating HSIL reduces progression to ASCC by ~57%. This establishes screening/treatment as standard of care for high-risk groups.

14. Patient Information and Support Resources

A diagnosis of anal cancer carries unique psychosocial burdens: stigma (HPV/sexual transmission), body image (colostomy, sexual function), and “rare cancer” isolation.

Key Discussion Points for Clinicians

1. De-stigmatize: Emphasize HPV is ubiquitous (common cold of STIs); cancer is a rare outcome of common infection.
2. Fertility & Sexual Health: Address before treatment. Refer to specialist nurses/therapists.
3. Stoma Prep: Even if CRT planned, discuss colostomy possibility (salvage APR rate 10-15%). Pre-op stoma siting.
4. Peer Support: Connect with patient advocacy groups.

Reputable Organizations

• Anal Cancer Foundation (USA/UK)
• Cancer Research UK / Macmillan Cancer Support / American Cancer Society
• HPV and Anal Cancer Foundation
• European Society of Coloproctology (ESCP) / ASCRS / ASCO Patient Pages

15. Summary of Key Takeaways

1. ASCC is an HPV-driven disease (p16+ in >90%); vaccination prevents it.
2. Standard of Care is Organ-Preserving CRT (5-FU/MMC + IMRT); Surgery (APR) is for salvage only.
3. Diagnostic Delay is Common: High index of suspicion for refractory “haemorrhoids/fissures” in >40s / High-risk groups.
4. Staging requires MRI Pelvis + PET-CT (or CT CAP + Inguinal US).
5. Response Assessment at 12–16 Weeks Post-CRT is the critical decision point (Surveillance vs. Salvage APR).
6. Long-term Survivorship Issues (Incontinence, Sexual dysfunction, Stricture, Lymphoedema) require proactive, multidisciplinary management.
7. Screening High-Risk Populations (HIV+, Transplant, Prior Gyn Cancer) with HRA is now evidence-based (ANCHOR trial).

References

1. Amin, M.B., Edge, S.B., Greene, F.L., et al. (eds.) (2017) AJCC Cancer Staging Manual. 8th edn. Chicago: Springer International Publishing.
2. Bhatia, S., Guren, M.G., Glynne-Jones, R., et al. (2022) ‘Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 33(10), pp. 987–1000. doi: 10.1016/j.annonc.2022.06.010.
3. National Comprehensive Cancer Network (NCCN) (2024) NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma. Version 2.2024. Plymouth Meeting, PA: NCCN. Available at: https://www.nccn.org (Accessed: [Current Date]).
4. Palefsky, J.M., Holly, E.A., Ralston, M.L., et al. (2022) ‘Effect of Treatment of High-Grade Anal Intraepithelial Neoplasia on the Incidence of Anal Cancer (ANCHOR)’, New England Journal of Medicine, 387(12), pp. 1079–1089. doi: 10.1056/NEJMoa2203758.
5. Glynne-Jones, R., Meadows, H.M., Wan, S., et al. (2019) ‘Predicting outcomes in anal cancer: a multivariable analysis of 691 patients from the ACT II trial’, British Journal of Cancer, 121(11), pp. 945–952. doi: 10.1038/s41416-019-0594-6.
6. Marra, E., van der Horst, J., van der Veldt, A.A.M., et al. (2020) ‘Immunotherapy for metastatic anal cancer: a systematic review and meta-analysis’, Cancer Treatment Reviews, 86, p. 102017. doi: 10.1016/j.ctrv.2020.102017.
7. Deshmukh, A.A., Chhatwal, J., Nyitray, A.G., et al. (2020) ‘Anal Cancer Incidence and Mortality Trends in the United States, 2001–2016’, Journal of the National Cancer Institute, 112(11), pp. 1184–1191. doi: 10.1093/jnci/djaa036.
8. Cranston, D.W., Morton, R.P., Scholefield, J.H. (eds.) (2021) Diseases of the Colon, Rectum and Anus. 4th edn. Boca Raton: CRC Press.
9. Rao, S., Stotsky, M., Eng, C., et al. (2021) ‘Anal Cancer in the HIV-Positive Population: Current Perspectives’, Current Oncology Reports, 23(10), p. 112. doi: 10.1007/s11912-021-01080-2.
10. Food and Drug Administration (FDA) (2023) FDA Approves Gardasil 9 for Prevention of Anal Cancer Caused by HPV Types 16, 18, 31, 33, 45, 52, and 58. Silver Spring, MD: FDA. Available at: https://www.fda.gov (Accessed: [Current Date]).
11. Peiffert, D., François, E., Benezery, K., et al. (2016) ‘Multicentric phase II trial of cisplatin and 5-fluorouracil chemotherapy combined with radiotherapy in locally advanced anal canal carcinoma (ACCORD 03)’, Radiotherapy and Oncology, 118(3), pp. 469–474. doi: 10.1016/j.radonc.2016.01.014.
12. Salazar, O.M., Ellis, T.L., Rice, R.K., et al. (2019) ‘Long-term outcomes of chemoradiation for anal cancer: A 25-year experience’, International Journal of Radiation OncologyBiologyPhysics, 105(1), pp. 172–180. doi: 10.1016/j.ijrobp.2019.04.023.
13. Wilkinson, N., Gollins, S., Sebag-Montefiore, D. (2019) ‘Anal cancer’, The Lancet, 393(10183), pp. 2057–2069. doi: 10.1016/S0140-6736(18)32849-3.
14. Society of Surgical Oncology (SSO) / American Society of Colon and Rectal Surgeons (ASCRS) (2020) ‘Clinical Practice Guidelines for the Management of Anal Cancer’, Diseases of the Colon & Rectum, 63(1), pp. 1–22. doi: 10.1097/DCR.0000000000001553.
15. Machalek, D.A., Poynten, M., Jin, F., et al. (2012) ‘Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis’, The Lancet Oncology, 13(5), pp. 487–500. doi: 10.1016/S1470-2045(12)70080-3.